Long-Term Survival of Cellulose Sulphate-Encapsulated Cells and Metronomic Ifosfamide Control Tumour Growth in Pancreatic Cancer Models—A Prelude to Treating Solid Tumours Effectively in Pets and Humans

Background: The use of encapsulated cells for the in vivo delivery of biotherapeutics is a promising new technology to potentiate the effectiveness of cell-based therapies for veterinary and human application. One use of the technology is to locally activate chemotherapeutics to their short-lived hi...

Full description

Bibliographic Details
Main Authors: Brian Salmons, Walter H. Gunzburg
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Life
Subjects:
Online Access:https://www.mdpi.com/2075-1729/13/12/2357
_version_ 1797380262572589056
author Brian Salmons
Walter H. Gunzburg
author_facet Brian Salmons
Walter H. Gunzburg
author_sort Brian Salmons
collection DOAJ
description Background: The use of encapsulated cells for the in vivo delivery of biotherapeutics is a promising new technology to potentiate the effectiveness of cell-based therapies for veterinary and human application. One use of the technology is to locally activate chemotherapeutics to their short-lived highly active forms. We have previously shown that a stable clone of HEK293 cells overexpressing a cytochrome P450 enzyme that has been encapsulated in immunoprotective cellulose sulphate beads can be implanted near solid tumours in order to activate oxazaphosphorines such as ifosfamide and cyclophosphamide to the tumour-killing metabolite phosphoramide mustard. The efficacy of this approach has been shown in animal models as well as in human and canine clinical trials. In these previous studies, the oxazaphosphorine was only given twice. An analysis of the Kaplan–Meier plots of the results of the clinical trials suggest that repeated dosing might result in a significant clinical benefit. Aims: In this study, we aimed to (i) demonstrate the stable long-term expression of cytochrome P450 from a characterized, transfected cell clone, as well as (ii) demonstrate that one implanted dose of these encapsulated cytochrome P450-expressing cells is capable of activating multiple doses of ifosfamide in animal models. Methodology: We initially used cell and molecular methods to show cell line stability over multiple passages, as well as chemical and biological function in vitro. This was followed by a demonstration that encapsulated HEK293 cells are capable of activating multiple doses of ifosfamide in a mouse model of pancreatic cancer without being killed by the chemotherapeutic. Conclusion: A single injection of encapsulated HEK293 cells followed by multiple rounds of ifosfamide administration results in repeated anti-tumour activity and halts tumour growth but, in the absence of a functioning immune system, does not cause tumour regression.
first_indexed 2024-03-08T20:35:52Z
format Article
id doaj.art-7935943e52b54f96a4e1d082563c468e
institution Directory Open Access Journal
issn 2075-1729
language English
last_indexed 2024-03-08T20:35:52Z
publishDate 2023-12-01
publisher MDPI AG
record_format Article
series Life
spelling doaj.art-7935943e52b54f96a4e1d082563c468e2023-12-22T14:21:25ZengMDPI AGLife2075-17292023-12-011312235710.3390/life13122357Long-Term Survival of Cellulose Sulphate-Encapsulated Cells and Metronomic Ifosfamide Control Tumour Growth in Pancreatic Cancer Models—A Prelude to Treating Solid Tumours Effectively in Pets and HumansBrian Salmons0Walter H. Gunzburg1Austrianova Singapore Pte Ltd., 2 International Business Park, The Strategy @ IBP #09-04, Singapore 609930, SingaporeInstitute of Virology, Department of Pathobiology, University of Veterinary Medicine, 1210 Vienna, AustriaBackground: The use of encapsulated cells for the in vivo delivery of biotherapeutics is a promising new technology to potentiate the effectiveness of cell-based therapies for veterinary and human application. One use of the technology is to locally activate chemotherapeutics to their short-lived highly active forms. We have previously shown that a stable clone of HEK293 cells overexpressing a cytochrome P450 enzyme that has been encapsulated in immunoprotective cellulose sulphate beads can be implanted near solid tumours in order to activate oxazaphosphorines such as ifosfamide and cyclophosphamide to the tumour-killing metabolite phosphoramide mustard. The efficacy of this approach has been shown in animal models as well as in human and canine clinical trials. In these previous studies, the oxazaphosphorine was only given twice. An analysis of the Kaplan–Meier plots of the results of the clinical trials suggest that repeated dosing might result in a significant clinical benefit. Aims: In this study, we aimed to (i) demonstrate the stable long-term expression of cytochrome P450 from a characterized, transfected cell clone, as well as (ii) demonstrate that one implanted dose of these encapsulated cytochrome P450-expressing cells is capable of activating multiple doses of ifosfamide in animal models. Methodology: We initially used cell and molecular methods to show cell line stability over multiple passages, as well as chemical and biological function in vitro. This was followed by a demonstration that encapsulated HEK293 cells are capable of activating multiple doses of ifosfamide in a mouse model of pancreatic cancer without being killed by the chemotherapeutic. Conclusion: A single injection of encapsulated HEK293 cells followed by multiple rounds of ifosfamide administration results in repeated anti-tumour activity and halts tumour growth but, in the absence of a functioning immune system, does not cause tumour regression.https://www.mdpi.com/2075-1729/13/12/2357cell therapyencapsulated cellsGDEPTmetronomictumour therapypancreatic cancer
spellingShingle Brian Salmons
Walter H. Gunzburg
Long-Term Survival of Cellulose Sulphate-Encapsulated Cells and Metronomic Ifosfamide Control Tumour Growth in Pancreatic Cancer Models—A Prelude to Treating Solid Tumours Effectively in Pets and Humans
Life
cell therapy
encapsulated cells
GDEPT
metronomic
tumour therapy
pancreatic cancer
title Long-Term Survival of Cellulose Sulphate-Encapsulated Cells and Metronomic Ifosfamide Control Tumour Growth in Pancreatic Cancer Models—A Prelude to Treating Solid Tumours Effectively in Pets and Humans
title_full Long-Term Survival of Cellulose Sulphate-Encapsulated Cells and Metronomic Ifosfamide Control Tumour Growth in Pancreatic Cancer Models—A Prelude to Treating Solid Tumours Effectively in Pets and Humans
title_fullStr Long-Term Survival of Cellulose Sulphate-Encapsulated Cells and Metronomic Ifosfamide Control Tumour Growth in Pancreatic Cancer Models—A Prelude to Treating Solid Tumours Effectively in Pets and Humans
title_full_unstemmed Long-Term Survival of Cellulose Sulphate-Encapsulated Cells and Metronomic Ifosfamide Control Tumour Growth in Pancreatic Cancer Models—A Prelude to Treating Solid Tumours Effectively in Pets and Humans
title_short Long-Term Survival of Cellulose Sulphate-Encapsulated Cells and Metronomic Ifosfamide Control Tumour Growth in Pancreatic Cancer Models—A Prelude to Treating Solid Tumours Effectively in Pets and Humans
title_sort long term survival of cellulose sulphate encapsulated cells and metronomic ifosfamide control tumour growth in pancreatic cancer models a prelude to treating solid tumours effectively in pets and humans
topic cell therapy
encapsulated cells
GDEPT
metronomic
tumour therapy
pancreatic cancer
url https://www.mdpi.com/2075-1729/13/12/2357
work_keys_str_mv AT briansalmons longtermsurvivalofcellulosesulphateencapsulatedcellsandmetronomicifosfamidecontroltumourgrowthinpancreaticcancermodelsapreludetotreatingsolidtumourseffectivelyinpetsandhumans
AT walterhgunzburg longtermsurvivalofcellulosesulphateencapsulatedcellsandmetronomicifosfamidecontroltumourgrowthinpancreaticcancermodelsapreludetotreatingsolidtumourseffectivelyinpetsandhumans